Systemic lupus erythematosus (SLE)

State of the Art: Lupus--the Future Is Now

Sunday, November 8, 2020

10:00 AM – 11:00 AM ET

Moderator(s)

Saira Sheikh, MD

Assistant Professor of Medicine
University of North Carolina at Chapel Hill

Speaker(s)

MC

Mary Crow, MD

Hospital for Special Surgery

There has been a historic drought of new therapies for SLE, with only one new FDA-approved medication in the last 50+ years. However, several lupus trials within the last year had positive results, bringing hope that new therapeutics may be available in the near future. This session will discuss how advances in our understanding of lupus pathogenesis have led to the development of different therapeutic strategies

Participants should be aware of the following financial/non-financial relationships:
Saira Z. Sheikh, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mary Crow, MD: Amgen: Stockholder; AstraZeneca, Bristol-Myers Squibb, Gilead, Lilly,: Consulting Fees (e.g., advisory boards); Johnson and Johnson: Stockholder; Merck: Stockholder; Pfizer: Stockholder; Principia Biopharma: Consulting Fees (e.g., advisory boards); Regeneron: Stockholder; Ventus: Consulting Fees (e.g., advisory boards)

Learning Objectives:

Describe how the historical knowledge of lupus pathogenesis resulted in the current lupus therapeutic strategies
Review how advances in knowledge of lupus pathogenesis have led to new approaches to lupus management
Provide potential avenues where lupus therapeutic management may evolve in the future

Presentations:

10:00 AM – 10:45 AM ET

State of the Art: Lupus--the Future Is Now
Mary Crow, MD – Hospital for Special Surgery
10:45 AM – 11:00 AM ET

Q&A